-
公开(公告)号：US20160263566A1
公开(公告)日：2016-09-15
申请号：US15164002
申请日：2016-05-25
Applicant: AbbVie Inc.
Inventor： Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
IPC: B01J31/24 , C07F9/6571 , C07C17/263 , C07C41/30 , C07F9/48 , C07F9/6558 , C07F9/6503 , C07F9/572 , C07F9/50 , C07C303/40 , C07D209/42 , C07D213/76 , C07D239/54 , C07C41/01 , C07C273/18 , C07C253/30 , C07C201/10 , C07D209/34 , C07C1/26 , C07F5/04 , C07C17/361 , C07D295/033 , C07C319/14 , C07C45/61 , C07F9/40 , C07F9/6568
CPC classification number: B01J31/2423 , B01J31/189 , B01J31/2419 , B01J31/2438 , B01J31/2466 , B01J31/2485 , B01J31/249 , B01J2231/4211 , B01J2231/4227 , B01J2231/4277 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2231/44 , B01J2531/0205 , B01J2531/0266 , B01J2531/0288 , B01J2531/824 , B01J2540/10 , B01J2540/40 , C07C1/26 , C07C1/30 , C07C1/321 , C07C17/093 , C07C17/2635 , C07C17/361 , C07C41/01 , C07C41/30 , C07C45/61 , C07C45/68 , C07C45/71 , C07C201/10 , C07C253/14 , C07C253/30 , C07C273/1854 , C07C273/1863 , C07C303/36 , C07C303/40 , C07C319/14 , C07C2531/24 , C07C2531/26 , C07D209/12 , C07D209/34 , C07D209/42 , C07D213/76 , C07D239/54 , C07D265/30 , C07D295/033 , C07F1/02 , C07F5/025 , C07F5/04 , C07F9/4021 , C07F9/4841 , C07F9/505 , C07F9/5072 , C07F9/509 , C07F9/572 , C07F9/65031 , C07F9/65583 , C07F9/65683 , C07F9/657163 , Y02P20/52 , C07C275/28 , C07C311/08 , C07C311/21 , C07C311/29 , C07C255/10 , C07C321/30 , C07C205/45 , C07C15/06 , C07C49/784
Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions.
-
公开(公告)号：US20150191437A1
公开(公告)日：2015-07-09
申请号：US14536192
申请日：2014-11-07
Applicant: AbbVie Inc.
Inventor： Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
IPC: C07D239/54 , A61K45/06 , A61K31/513
CPC classification number: C07D239/54 , A61K31/513 , A61K31/7056 , A61K38/21 , A61K45/06 , B01J31/2423 , B01J2231/4211 , B01J2231/4227 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2231/49 , B01J2531/824 , C07D239/10 , A61K2300/00
Abstract: This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions.
Abstract translation: 本公开涉及：（a）制备其特别是可用于抑制丙型肝炎病毒（HCV）的化合物及其盐的方法; （b）可用于制备化合物和盐的中间体; （c）包含所述化合物或盐的药物组合物; 和（d）使用这种组合物的方法。
-
公开(公告)号：US08841487B2
公开(公告)日：2014-09-23
申请号：US13184425
申请日：2011-07-15
Applicant: Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
Inventor： Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
IPC: C07F9/6568 , C07F9/6503 , C07F9/655
CPC classification number: C07F9/657163 , B01J31/189 , B01J31/2423 , B01J31/2466 , B01J31/2485 , B01J31/249 , B01J2231/344 , B01J2231/4227 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2531/0205 , B01J2531/0266 , B01J2531/0288 , B01J2531/824 , B01J2540/10 , B01J2540/40 , C07C1/30 , C07C1/321 , C07C15/14 , C07C17/093 , C07C17/361 , C07C41/09 , C07C45/68 , C07C201/10 , C07C253/30 , C07C273/1854 , C07C273/1863 , C07C303/40 , C07C315/04 , C07C319/14 , C07C319/18 , C07C2523/42 , C07C2523/44 , C07C2523/46 , C07C2523/52 , C07C2523/72 , C07C2523/75 , C07C2523/755 , C07C2527/14 , C07C2531/22 , C07C2531/24 , C07D209/34 , C07D239/54 , C07D295/033 , C07F5/027 , C07F9/40 , C07F9/65031 , C07F9/65515 , C07F9/6552 , C07F9/65683 , C07F9/6571 , C07F9/6584 , Y02P20/52 , C07C275/28 , C07C311/08 , C07C311/21 , C07C311/29 , C07C255/10 , C07C321/30 , C07C205/45 , C07C15/06 , C07C49/784 , C07C25/18
Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands.
Abstract translation: 本公开涉及：（a）磷酸基配体; （b）在成键反应中使用这种磷酸基配体的方法; 和（c）制备磷酸基配体的方法。
-
4.发明授权公开(公告)号：US06727377B2
公开(公告)日：2004-04-27
申请号：US09992551
申请日：2001-11-06
Applicant: Xumu Zhang
Inventor： Xumu Zhang
IPC: C07F9655
CPC classification number: C07F17/02 , B01J31/1658 , B01J31/2295 , B01J31/2423 , B01J31/2433 , B01J31/2466 , B01J31/2476 , B01J2231/323 , B01J2231/324 , B01J2231/342 , B01J2231/348 , B01J2231/4205 , B01J2231/4261 , B01J2231/643 , B01J2231/645 , B01J2531/0205 , B01J2531/0266 , B01J2531/821 , B01J2531/822 , B01J2531/824 , B01J2531/827 , B01J2531/842 , B01J2531/847 , C07B53/00 , C07C45/505 , C07F9/65683 , C07F9/65719 , C07F15/0006 , C07F15/0033 , C07F15/0046 , C07F15/006 , C07F15/0073 , C07F15/04
Abstract: Chiral phosphine ligands derived from chiral natural products including D-mannitol and tartaric acid. The ligands contain one or more 5-membered phospholane rings with multiple chiral centers, and provide high stereoselectivity in asymmetric reactions.
Abstract translation: 衍生自手性天然产物的手性膦配体，包括D-甘露糖醇和酒石酸。 配体含有一个或多个具有多个手性中心的5元磷脂环，并且在不对称反应中提供高立体选择性。
-
公开(公告)号：US09669399B2
公开(公告)日：2017-06-06
申请号：US15164002
申请日：2016-05-25
Applicant: AbbVie Inc.
Inventor： Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
IPC: C07F9/6568 , C07C303/40 , B01J31/24 , C07D209/12 , C07D213/76 , C07D239/54 , C07C253/30 , C07C201/10 , C07D209/34 , C07D265/30 , C07C1/30 , C07C17/093 , C07C41/01 , C07C45/71 , C07C253/14 , C07C273/18 , C07C303/36 , C07C319/14 , C07D209/42 , C07D295/033 , C07F5/02 , C07F9/40 , C07C1/32 , C07C45/68 , C07F1/02 , C07F9/50 , C07C1/26 , C07C17/263 , C07C17/361 , C07C41/30 , C07C45/61 , C07F5/04 , C07F9/48 , C07F9/572 , C07F9/6503 , C07F9/6558 , C07F9/6571 , B01J31/18
CPC classification number: B01J31/2423 , B01J31/189 , B01J31/2419 , B01J31/2438 , B01J31/2466 , B01J31/2485 , B01J31/249 , B01J2231/4211 , B01J2231/4227 , B01J2231/4277 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2231/44 , B01J2531/0205 , B01J2531/0266 , B01J2531/0288 , B01J2531/824 , B01J2540/10 , B01J2540/40 , C07C1/26 , C07C1/30 , C07C1/321 , C07C17/093 , C07C17/2635 , C07C17/361 , C07C41/01 , C07C41/30 , C07C45/61 , C07C45/68 , C07C45/71 , C07C201/10 , C07C253/14 , C07C253/30 , C07C273/1854 , C07C273/1863 , C07C303/36 , C07C303/40 , C07C319/14 , C07C2531/24 , C07C2531/26 , C07D209/12 , C07D209/34 , C07D209/42 , C07D213/76 , C07D239/54 , C07D265/30 , C07D295/033 , C07F1/02 , C07F5/025 , C07F5/04 , C07F9/4021 , C07F9/4841 , C07F9/505 , C07F9/5072 , C07F9/509 , C07F9/572 , C07F9/65031 , C07F9/65583 , C07F9/65683 , C07F9/657163 , Y02P20/52 , C07C275/28 , C07C311/08 , C07C311/21 , C07C311/29 , C07C255/10 , C07C321/30 , C07C205/45 , C07C15/06 , C07C49/784
Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions.
-
Patent Agency Ranking
公开(公告)号：US20160332973A1
公开(公告)日：2016-11-17
申请号：US15221156
申请日：2016-07-27
Applicant: AbbVie Inc.
Inventor： Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
IPC: C07D239/54 , A61K31/513
CPC classification number: C07D239/54 , A61K31/513 , A61K31/7056 , A61K38/21 , A61K45/06 , B01J31/2423 , B01J2231/4211 , B01J2231/4227 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2231/49 , B01J2531/824 , C07D239/10 , A61K2300/00
Abstract: This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions.
-
公开(公告)号：US09434698B2
公开(公告)日：2016-09-06
申请号：US14536192
申请日：2014-11-07
Applicant: AbbVie Inc.
Inventor： Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
IPC: C07D239/54 , A61K31/505 , B01J31/24 , C07D239/10 , A61K31/513 , A61K45/06 , A61K38/21 , A61K31/7056
CPC classification number: C07D239/54 , A61K31/513 , A61K31/7056 , A61K38/21 , A61K45/06 , B01J31/2423 , B01J2231/4211 , B01J2231/4227 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2231/49 , B01J2531/824 , C07D239/10 , A61K2300/00
Abstract: This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions.
-
8.发明授权公开(公告)号：US06946569B2
公开(公告)日：2005-09-20
申请号：US10791320
申请日：2004-03-02
Applicant: Xumu Zhang
Inventor： Xumu Zhang
IPC: C07D213/55 , B01J31/22 , B01J31/24 , C07B53/00 , C07B61/00 , C07C45/50 , C07C51/36 , C07C55/02 , C07C67/303 , C07C69/34 , C07C231/12 , C07C231/18 , C07C233/47 , C07F9/6568 , C07F9/6571 , C07F15/00 , C07F15/04 , C07F17/02 , C07F19/00 , C07F9/655
CPC classification number: C07F17/02 , B01J31/1658 , B01J31/2295 , B01J31/2423 , B01J31/2433 , B01J31/2466 , B01J31/2476 , B01J2231/323 , B01J2231/324 , B01J2231/342 , B01J2231/348 , B01J2231/4205 , B01J2231/4261 , B01J2231/643 , B01J2231/645 , B01J2531/0205 , B01J2531/0266 , B01J2531/821 , B01J2531/822 , B01J2531/824 , B01J2531/827 , B01J2531/842 , B01J2531/847 , C07B53/00 , C07C45/505 , C07F9/65683 , C07F9/65719 , C07F15/0006 , C07F15/0033 , C07F15/0046 , C07F15/006 , C07F15/0073 , C07F15/04
Abstract: Chiral phosphine ligands derived from chiral natural products including D-mannitol and tartaric acid. The ligands contain one or more 5-membered phospholane rings with multiple chiral centers, and provide high stereoselectivity in asymmetric reactions.
Abstract translation: 衍生自手性天然产物的手性膦配体，包括D-甘露糖醇和酒石酸。 配体含有一个或多个具有多个手性中心的5元磷脂环，并且在不对称反应中提供高立体选择性。
-
公开(公告)号：US3496204A
公开(公告)日：1970-02-17
申请号：US3496204D
申请日：1968-09-09
Applicant: SHELL OIL CO
Inventor： MORRIS RUPERT C , WINKLE JOHN L VAN , MASON RONALD F
IPC: B01J31/24 , C07C45/49 , C07C45/50 , C07F9/6568 , C07F15/06 , B01J11/22 , C07D105/02
CPC classification number: C07F15/065 , B01J31/188 , B01J31/20 , B01J31/2423 , B01J2231/321 , B01J2531/0205 , B01J2531/845 , C07C45/49 , C07C45/50 , C07F9/65683 , C10M2209/00 , C10M2209/02 , C10M2209/10 , C10M2223/06 , C10M2223/061 , C07C47/14 , C07C47/30 , C07C47/228
-
公开(公告)号：US20150360215A1
公开(公告)日：2015-12-17
申请号：US14834420
申请日：2015-08-24
Applicant: AbbVie Inc.
Inventor： Shashank Shekhar , Thaddeus S. Franczyk , David M. Barnes , Travis B. Dunn , Anthony R. Haight , Vincent S. Chan
IPC: B01J31/24 , C07D209/42 , C07F9/50 , C07D239/54 , C07F1/02 , C07F9/40 , C07C303/40 , C07D213/76
CPC classification number: B01J31/2423 , B01J31/189 , B01J31/2419 , B01J31/2438 , B01J31/2466 , B01J31/2485 , B01J31/249 , B01J2231/4211 , B01J2231/4227 , B01J2231/4277 , B01J2231/4283 , B01J2231/4288 , B01J2231/4294 , B01J2231/44 , B01J2531/0205 , B01J2531/0266 , B01J2531/0288 , B01J2531/824 , B01J2540/10 , B01J2540/40 , C07C1/26 , C07C1/30 , C07C1/321 , C07C17/093 , C07C17/2635 , C07C17/361 , C07C41/01 , C07C41/30 , C07C45/61 , C07C45/68 , C07C45/71 , C07C201/10 , C07C253/14 , C07C253/30 , C07C273/1854 , C07C273/1863 , C07C303/36 , C07C303/40 , C07C319/14 , C07C2531/24 , C07C2531/26 , C07D209/12 , C07D209/34 , C07D209/42 , C07D213/76 , C07D239/54 , C07D265/30 , C07D295/033 , C07F1/02 , C07F5/025 , C07F5/04 , C07F9/4021 , C07F9/4841 , C07F9/505 , C07F9/5072 , C07F9/509 , C07F9/572 , C07F9/65031 , C07F9/65583 , C07F9/65683 , C07F9/657163 , Y02P20/52 , C07C275/28 , C07C311/08 , C07C311/21 , C07C311/29 , C07C255/10 , C07C321/30 , C07C205/45 , C07C15/06 , C07C49/784
Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions.
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.021 seconds)
